The role of ALP as predictor of CV events and vascular calcification in CKD10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD – Stockholm, Sweden
Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.
Video navigation menu
- What is alkaline phosphatase and where can it be found? 1:08
- ALP-related mechanisms of increased CV 2:38
- Reduced ALP-related CV risk with apabetalone 8:44
This lecture by dr. Mathias Haarhaus, was part of an accredited symposium "Vascular calcification in kidney disease: Epigenetics as a novel approach?" held during ERA-EDTA 2019 in Budapest, Hungary.
Dr. Mathias Haarhaus, MD, Consultant Nephrologist at the Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.